Total Payments
$4,153
2024 Payments
$1,212
Companies
3
Transactions
28
Payment Breakdown by Category
Research$2,486 (59.8%)
Travel$1,179 (28.4%)
Food & Beverage$488.95 (11.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,486 | 23 | 59.8% |
| Travel and Lodging | $1,179 | 3 | 28.4% |
| Food and Beverage | $488.95 | 2 | 11.8% |
Payments by Type
Research
$2,486
23 transactions
General
$1,668
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $1,561 | 4 | $0 (2017) |
| ABBVIE INC. | $1,319 | 12 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,273 | 12 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,212 | 11 | ABBVIE INC. ($1,212) |
| 2022 | $107.09 | 1 | ABBVIE INC. ($107.09) |
| 2018 | $1,273 | 12 | SANOFI US SERVICES INC. ($1,273) |
| 2017 | $1,561 | 4 | PFIZER INC. ($1,561) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/14/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $293.12 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $69.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/12/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $125.05 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $70.25 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $50.54 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $37.50 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/11/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 04/10/2024 | ABBVIE INC. | ARMOUR THYROID (Drug) | — | In-kind items and services | $226.86 | Research |
| Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID | ||||||
| 02/24/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $107.09 | General |
| Category: NEUROSCIENCE | ||||||
| 09/29/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $13.99 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/29/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $13.82 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $103.56 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $60.44 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/28/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $29.81 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $373.32 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $269.87 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $239.05 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | In-kind items and services | $100.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $13.98 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 09/27/2018 | SANOFI US SERVICES INC. | SAR439954 (Drug) | — | Cash or cash equivalent | $5.58 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | ||||||
| 08/03/2017 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $814.40 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | SANOFI US SERVICES INC. | $1,273 | 12 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,212 | 11 |
About Dr. Kenneth Aung-Din, MD
Dr. Kenneth Aung-Din, MD is a Emergency Medicine healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003912759.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Aung-Din, MD has received a total of $4,153 in payments from pharmaceutical and medical device companies, with $1,212 received in 2024. These payments were reported across 28 transactions from 3 companies. The most common payment nature is "" ($2,486).
Ad
Practice Information
- Specialty Emergency Medicine
- Location Jacksonville, FL
- Active Since 09/16/2006
- Last Updated 07/08/2007
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1003912759
Products in Payments
- SAR439954 (Drug) $1,273
- ARMOUR THYROID (Drug) $1,212
- UBRELVY (Drug) $107.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Jacksonville
Dr. Robert Luten, M.d, M.D
Emergency Medicine — Payments: $278,828
Emergency Medicine $278,828
Dr. Arin Piramzadian, D.o, D.O
Emergency Medicine — Payments: $100,431
Emergency Medicine $100,431
Daniel D'amore, M.d, M.D
Emergency Medicine — Payments: $44,473
Emergency Medicine $44,473
Dr. Brian Meyer, Md, MD
Emergency Medicine — Payments: $14,821
Emergency Medicine $14,821
Dr. Joseph Shiber, Md, MD
Emergency Medicine — Payments: $9,760
Emergency Medicine $9,760
Petra Duran-Gehring, Md, MD
Emergency Medicine — Payments: $9,053
Emergency Medicine $9,053